STVN
Stevanato Group S.p.A.Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EBITDA non-GAAP | 65.5M | first quarter of 2026 call | — |
| adjusted EBITDA margin non-GAAP | 23.9% | first quarter of 2026 call | — |
| biologics revenue growth | 15% | first quarter of 2026 call | — |
| capital expenditures | 67.6M | first quarter of 2026 call | — |
| Engineering Segment revenue decline | -31% | first quarter of 2026 call | — |
| high-value solutions as a percent of BDS segment revenue | 52% | first quarter of 2026 call | — |
| other containment and delivery solutions revenue | 120.3M | first quarter of 2026 call | — |
| revenue from high-value solutions | 128.6M | first quarter of 2026 call | — |
| syringe revenue growth | 20% | first quarter of 2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STVN
this stock
Stevanato Group S.p.A.
|
$5.40B | -1.7% | — | — | 1.9% |
|
ISRG
Intuitive Surgical Inc
|
$144.19B | -28.1% | +20.5% | 49.5 | 2.1% |
|
MDLN
Medline Inc.
|
$53.31B | -3.4% | +11.5% | — | 2.8% |
|
BDX
Becton Dickinson & Co
|
$42.39B | +2.2% | +8.2% | 58.5 | 4.1% |
|
ALC
Alcon Inc
|
$33.65B | -12.4% | +10.5% | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STVN | +2.6% | +14.4% | +0.2% | +9.5% | -1.7% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | +2.9% | +12.9% | -8.2% | +9.1% | -11.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.